Form 4: Director Roy D. Baynes Executes Travere Stock Options

Director Roy D. Baynes exercised stock options and sold 32,750 shares of Travere Therapeutics, Inc. common stock.

Summary

• Director Roy D. Baynes exercised options to acquire 32,750 shares of common stock at various strike prices ranging from $15.43 to $21.38.
• Following the exercise, the director sold 32,750 shares in two tranches at prices of $41.07 and $42.12 per share.
• The transactions were executed pursuant to a Rule 10b5-1(c) trading plan adopted on November 17, 2025.
• The director's total beneficial ownership of common stock stands at 37,500 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard portfolio management by a director.

Positives

• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without concerns regarding non-public information.

Negatives

• The director reduced their direct beneficial ownership stake in the company through these sales.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in the company's short-term growth prospects, although these sales were pre-planned.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under 10b5-1 plans, are common in the biotechnology sector as executives and directors manage their personal equity compensation portfolios.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to ensure compliance with securities laws while liquidating equity holdings.

Stakeholder Impact

• Shareholders should note the reduction in the director's direct equity stake, though the pre-planned nature of the sale mitigates concerns regarding insider sentiment.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Travere Therapeutics, TVTX, Insider Trading, Form 4, Stock Options, Director